Trials / Unknown
UnknownNCT04854759
The Use of Amantadine in the Prevention of Progression and Treatment of COVID-19 Symptoms
The Use of Amantadine in the Prevention of Progression and Treatment of COVID-19 Symptoms in Patients Infected With the SARS-CoV-2 Virus
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Independent Public Clinical Hospital No. 4 in Lublin · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The use of amantadine in the prevention of progression and treatment of COVID-19 symptoms in patients infected with the SARS-CoV-2 virus. Multicenter randomized, double-blind, placebo-controlled, non-commercial clinical trial
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Amantadine Hydrochloride | 100 mg, capsule |
| DRUG | Placebo | 100 mg, capsule |
Timeline
- Start date
- 2021-03-15
- Primary completion
- 2022-03-31
- Completion
- 2022-05-31
- First posted
- 2021-04-22
- Last updated
- 2021-08-13
Locations
8 sites across 1 country: Poland
Source: ClinicalTrials.gov record NCT04854759. Inclusion in this directory is not an endorsement.